Journal of Neurology

, Volume 263, Issue 5, pp 883–887 | Cite as

Plasma exchange response in 34 patients with severe optic neuritis

  • Romain DeschampsEmail author
  • Antoine Gueguen
  • Nathalie Parquet
  • Samir Saheb
  • Francoise Driss
  • Malcie Mesnil
  • Catherine Vignal
  • Jennifer Aboab
  • Raphael Depaz
  • Olivier Gout
Original Communication


Optic neuritis could lead to severe visual impairment despite corticosteroids. Our aim was to evaluate the rate of visual improvement in patients treated with plasma exchange (PLEX) for severe steroid unresponsive optic neuritis and to identify predictive factors of outcome. Thirty-four patients (41 optic nerves damaged) with remaining visual acuity of 0.1 or less despite steroid pulse therapy were treated with PLEX from September 2010 to May 2015. Demographic and clinical neuro-ophthalmic findings, and spectral domain-optical coherence tomography data before PLEX treatment were analyzed. The mean symptom duration before PLEX was 34.6 days (median 28 days; range 6–92 days). After PLEX, the median final visual acuity was 0.8 and in 56 % of cases, final acuity was 0.5 or better. Past history of ipsilateral optic neuritis was associated significantly with poor outcome defined as final acuity less than 0.5. No significant difference in the visual outcome after PLEX was found between multiple sclerosis and neuromyelitis optica. In conclusion, this observational study showed that PLEX as second-line therapy led to a functionally important visual recovery in more than half patients with severe optic neuritis.


Plasmapheresis Optic neuritis Corticosteroids Multiple sclerosis Neuromyelitis optica Myelin oligodendrocyte glycoprotein 


Compliance with ethical standards

Ethical standards

This study was approved by our institutional review board.

Conflicts of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.


  1. 1.
    Beck RW, Cleary PA (1993) Optic neuritis treatment trial. One-year follow-up results. Arch Ophthalmol 111:773–775CrossRefPubMedGoogle Scholar
  2. 2.
    Weinshenker BG, O’Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, Pineda AA, Stevens LN, Rodriguez M (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46:878–888CrossRefPubMedGoogle Scholar
  3. 3.
    Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A (2011) Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the therapeutics and technology assessment subcommittee of the american academy of neurology. Neurology 76:294–300CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Gwathmey K, Balogun RA, Burns T (2012) Neurologic indications for therapeutic plasma exchange: 2011 update. J Clin Apher 27:138–145CrossRefPubMedGoogle Scholar
  5. 5.
    Pula JH, Glisson CC (2015) Should plasma exchange be offered to patients with multiple sclerosis-associated optic neuritis? J Neuroophthalmol 35:86–89CrossRefPubMedGoogle Scholar
  6. 6.
    Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6:805–815CrossRefPubMedGoogle Scholar
  7. 7.
    Polman C, Reingold S, Banwell B (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Petzold A, Pittock S, Lennon V, Maggiore C, Weinshenker BG, Plant GT (2010) Neuromyelitis optica-IgG (aquaporin-4) auto-antibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatry 81:109–111CrossRefPubMedGoogle Scholar
  9. 9.
    Ruprecht K, Klinker E, Dintelmann T, Rieckmann P, Gold R (2004) Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology 63:1081–1083CrossRefPubMedGoogle Scholar
  10. 10.
    Roesner S, Appel R, Gbadamosi J, Martin R, Heesen C (2012) Treatment of steroid-unresponsive optic neuritis with plasma exchange. Acta Neurol Scand 126:103–108CrossRefPubMedGoogle Scholar
  11. 11.
    Trebst C, Reising A, Kielstein JT, Hafer C, Stangel M (2009) Plasma exchange therapy in steroid-unresponsive relapses in patients with multiple sclerosis. Blood Purif 28:108–115CrossRefPubMedGoogle Scholar
  12. 12.
    Heigl F, Hettich R, Arendt R, Durner J, Koehler J, Mauch E (2013) Immunoadsorption in steroid-refractory multiple sclerosis: clinical experience in 60 patients. Atheroscler Suppl 14:167–173CrossRefPubMedGoogle Scholar
  13. 13.
    Koziolek MJ, Tampe D, Bähr M, Dihazi H, Jung K, Fitzner D, Klingel R, Müller GA, Kitze B (2012) Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis. J Neuroinflammation 26:80. doi: 10.1186/1742-2094-9-80 Google Scholar
  14. 14.
    Schilling S, Linker RA, König FB, Koziolek M, Bähr M, Müller GA, Paulus W, Gärtner J, Brück W, Chan A, Gold R (2006) Plasma exchange therapy for steroid-unresponsive multiple sclerosis relapses: clinical experience with 16 patients. Nervenarzt 77:430–438CrossRefPubMedGoogle Scholar
  15. 15.
    Merle H, Olindo S, Jeannin S, Valentino R, Mehdaoui H, Cabot F, Donnio A, Hage R, Richer R, Smadja D, Cabre P (2012) Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch Ophthalmol 130(7):858–862CrossRefPubMedGoogle Scholar
  16. 16.
    Mühlhausen J, Kitze B, Huppke P, Müller GA, Koziolek MJ (2015) Apheresis in treatment of acute inflammatory demyelinating disorders. Atheroscler Suppl 18:251–256CrossRefPubMedGoogle Scholar
  17. 17.
    Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG (2002) Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 58:143–146CrossRefPubMedGoogle Scholar
  18. 18.
    Magaña SM, Keegan BM, Weinshenker BG, Erickson BJ, Pittock SJ, Lennon VA, Rodriguez M, Thomsen K, Weigand S, Mandrekar J, Linbo L, Lucchinetti CF (2011) Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol 68:870–878CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Kupersmith MJ, Gal RL, Beck RW, Xing D, Miller N; Optic Neuritis Study Group (2007) Visual function at baseline and 1 month in acute optic neuritis: predictors of visual outcome. Neurology 69:508–514CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Romain Deschamps
    • 1
    Email author
  • Antoine Gueguen
    • 1
  • Nathalie Parquet
    • 2
  • Samir Saheb
    • 3
  • Francoise Driss
    • 4
  • Malcie Mesnil
    • 5
  • Catherine Vignal
    • 6
  • Jennifer Aboab
    • 1
  • Raphael Depaz
    • 1
  • Olivier Gout
    • 1
  1. 1.Service de NeurologieFondation Ophtalmologique Adolphe de RothschildParisFrance
  2. 2.Unité d’hémaphérèse thérapeutiqueHôpital Saint-Louis, APHPParisFrance
  3. 3.Service d’hématologie clinique et de Thérapie CellulaireHôpital de la Pitié-Salpêtrière, AP-HPParisFrance
  4. 4.Unité de thérapeutique transfusionnelleHôpital universitaire Bicêtre, AP-HPLe Kremlin-BicêtreFrance
  5. 5.Département d’anesthésie réanimationFondation Ophtalmologique Adolphe de RothschildParisFrance
  6. 6.Service d’ophtalmologieFondation Ophtalmologique Adolphe de RothschildParisFrance

Personalised recommendations